Gene
IL7R
IL7R is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Assay-provider ledger (29), Actionable biomarkers (4), Trial mentions (7), and 6 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
1 more section with rows · 3 sections measured, none recorded
Cancer actionable (CGI)
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention IL7R. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers. Not plotted: 19 at the structurally incomplete recent edge.
IL7R has 7 trial mentions across 6 years. That is too few to read as a trend, so the years are listed instead.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 0 of 8,738 | 0.00% | not measured | |
| 2025 | 2 of 8,875 | 0.02% | not measured | |
| 2024 | 1 of 8,597 | 0.01% | not measured | |
| 2023 | 0 of 8,275 | 0.00% | 59 of 11,460 | 0.51% |
| 2022 | 0 of 8,285 | 0.00% | 78 of 13,598 | 0.57% |
| 2021 | 0 of 8,692 | 0.00% | 80 of 15,045 | 0.53% |
| 2020 | 0 of 7,640 | 0.00% | 89 of 14,459 | 0.62% |
| 2019 | 1 of 7,300 | 0.01% | 60 of 12,159 | 0.49% |
| 2018 | 1 of 6,927 | 0.01% | 58 of 11,854 | 0.49% |
| 2017 | 1 of 6,558 | 0.02% | 47 of 11,595 | 0.41% |
Showing 10 of 37 years.
Assay-provider ledger (29)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| OLINK AB | Reagent supplier | Clinical validationAnalytical validation | 2 | August 01, 2026 |
| SOMALogic, Inc | Reagent supplier | Clinical validationAnalytical validation | 1 | August 01, 2026 |
| OLINK Proteomics | Reagent supplier | Clinical validation | 1 | February 02, 2026 |
| UK Biobank Pharma Proteomics Project | Not a company | Clinical validation | 1 | February 02, 2026 |
| PreAnalytiX | Reagent supplier | Clinical validation | 1 | April 01, 2024 |
Showing 5 of 29 assay-provider companies.
Actionable biomarkers (4)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| IL7R (S185C) + SH2B3 deletion | Mtor Inhibitors | response-associated | acute lymphoblastic leukemia | Cancer Genome Interpreter |
| IL7R inframe insertion (237-255),inframe deletion (237-255) + SH2B3 deletion | Mtor Inhibitors | response-associated | acute lymphoblastic leukemia | Cancer Genome Interpreter |
| IL7R (S185C) + SH2B3 deletion | Ruxolitinib | response-associated | acute lymphoblastic leukemia | Cancer Genome Interpreter |
| IL7R inframe insertion (237-255),inframe deletion (237-255) + SH2B3 deletion | Ruxolitinib | response-associated | acute lymphoblastic leukemia | Cancer Genome Interpreter |
Trial mentions (7)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT02963064 | Trial eligibility (AACT) |
| NCT03571321 | Trial eligibility (AACT) |
| NCT03705507 | Trial eligibility (AACT) |
| NCT05745714 | Trial eligibility (AACT) |
| NCT07003737 | Trial eligibility (AACT) |
Showing 5 of 7 trial mentions.
Target-disease associations (574)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| 22q11.2 deletion syndrome | cardiovascular disease | Mouse knockout (IMPC) |
| 3-aminoisobutyrate measurement | measurement | GWAS credible sets |
| AIDS | genetic, familial or congenital disease | Literature (Europe PMC) |
| AMED syndrome, digenic | genetic, familial or congenital disease | Mouse knockout (IMPC) |
| Aarskog-Scott syndrome, X-linked | genetic, familial or congenital disease | Literature (Europe PMC) |
Showing 5 of 574 associations.
Vendor sourcing (52)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| 3billion, Inc. (South Korea) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The variant is observed at an extremely low frequency in the gnomAD v2.1.1 dataset (total allele frequency: <0.001%). This variant was predicted to alter spl... | View ClinVar record SCV003841973.1 |
| Ambry Genetics (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The c.1256T>C (p.F419S) alteration is located in exon 8 (coding exon 8) of the IL7R gene. This alteration results from a T to C substitution at nucleotide po... | View ClinVar record SCV003528322.2 |
| Astrazeneca Plc | Trial collaborator | Named in trial inclusion criteriaTrial eligibility criteria | : * Morphologically proven relapsed/refractory (M2 or M3 marrow; ≥1st relapse for adults, ≥2nd relapse in paediatric group - see Protocol Appendix 5) or pro... | View trial NCT03705507 |
| Astrazeneca Plc | Trial collaborator | Mentioned in trial textTrial free-text mention | IL7R | View trial NCT03705507 |
| Baylor College of Medicine | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | No supporting text recorded; see the citation. | View ClinVar record SCV001334109.1 |
Showing 5 of 52 sourcing records.
Trial-cited literature (811)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| Zamtocabtagene Autoleucel in Relapsed/refractory B-NHL: 5-year Follow Up of a CD20/19 tandem CAR T Cell Phase 1 Trial. | Blood advances | 2026 | 2 |
| Reciprocal regulation of hMENA and TGF-β signaling in cancer-associated fibroblasts promotes EMT, immunosuppression, poor prognosis, and ICT resistance in NSCLC. | Journal for immunotherapy of cancer | 2026 | 1 |
| Biomarkers of activity from a phase I study of cergutuzumab amunaleukin in patients with advanced solid tumors. | Journal for immunotherapy of cancer | 2026 | 1 |
| Bimekizumab long-term response in psoriasis: Mechanistic insights into efficacy level and durability. | The Journal of allergy and clinical immunology | 2026 | 0 |
| Fecal microbiota transplantation for refractory chronic graft-versus-host disease after allogeneic hematopoietic cell transplantation: a pilot open-label, non-placebo-controlled study. | BMC medicine | 2025 | 7 |
Showing 5 of 811 papers.
Protein variant mentions (38)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.A019D | 2 | 2023 to 2024 | PMID 38184304, PMID 36754451 |
| p.A24F | 1 | 2014 | PMID 25396066 |
| p.A260T | 1 | 2015 | PMID 25741868 |
| p.A26M | 1 | 2014 | PMID 25396066 |
| p.A43F | 1 | 2014 | PMID 25396066 |
Showing 5 of 38 variants.
Literature-extracted relations (54)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| RITUXIMAB | Chemical | associate |
Effects of rituximab therapy on B cell differentiation and depletion. | 2020 |
| Alemtuzumab | Chemical | positive_correlate |
IL-7 receptor heterogeneity as a mechanism for repertoire change during postdepletional homeostatic proliferation and its relation to costimulation blockade-resistant rejection. | 2018 |
| Estriol | Chemical | positive_correlate |
Neutrophils induce proangiogenic T cells with a regulatory phenotype in pregnancy. | 2016 |
| Progesterone | Chemical | positive_correlate |
Neutrophils induce proangiogenic T cells with a regulatory phenotype in pregnancy. | 2016 |
| fatty acids, omega-3 | Chemical | positive_correlate |
Adipose tissue RNASeq reveals novel gene-nutrient interactions following n-3 PUFA supplementation and evoked inflammation in humans. | 2016 |
Showing 5 of 54 relation assertions.
Organizations publishing (605)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| Government of the United States of America | Government | 66 | 1998 to 2024 |
| University of California System | Academic | 26 | 2013 to 2022 |
| Harvard Medical School | Academic | 25 | 2010 to 2025 |
| Mass General Brigham | Hospital | 25 | 2007 to 2023 |
| Memorial Sloan Kettering Cancer Center | Hospital | 22 | 2014 to 2024 |
Showing 5 of 605 organizations.
Where IL7R appears
- animal disease
- biological_process
- cancer or benign tumor
- cardiovascular disease
- disorder of ear
- disorder of visual system
- endocrine system disease
- gastrointestinal disease
- genetic, familial or congenital disease
- hematologic disease
- immune system disease
- infectious disease
- integumentary system disease
- measurement
- musculoskeletal or connective tissue disease
- nervous system disease
- nutritional or metabolic disease
- phenotype
- respiratory or thoracic disease
- urinary system disease
517 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions, fda biomarker qualification projects, and human sample screening reference.